Buffalo Sabres goaltender Dustin Tokarski made his first appearance in an NHL game since October 26, 2016 in a loss to the New York Rangers and the he discussed how it felt.
Buffalo Sabres goaltender Dustin Tokarski made his first appearance in an NHL game since October 26, 2016 in a loss to the New York Rangers and the he discussed how it felt.
Here is all you need to know about the Match 13 of the IPL between Delhi Capitals and Mumbai Indians.
The "Global Aftermarket for Motorcycle Full Exhaust Systems Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
Benjamin Hunt, 32, from Longton, Staffordshire, pleaded guilty to manslaughter.
KEY FINDINGS The global peripheral artery disease market is projected to grow at a CAGR of 10. 35% during the forecast period, 2021-2028. The market growth is propelled by technological advancements in treatment, increasing geriatric population, healthcare infrastructure, and improving reimbursement and insurance policies in developing economies.New York, April 19, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "GLOBAL PERIPHERAL ARTERY DISEASE MARKET FORECAST 2021-2028" - https://www.reportlinker.com/p06064352/?utm_source=GNW MARKET INSIGHTSPeripheral artery disease (PAD) is a disease of blood vessels located outside the heart and brain.It occurs due to plaque build-up in arteries that carry blood to limbs, organs, and head.One of the primary drivers of market growth is enhanced insurance and reimbursement policies. Governments across the world are striving to provide quality healthcare for their population.Moreover, health issue awareness, health insurance promotion, and ensuring strong infrastructure are among the authorities’ activities for people’s welfare.In 2017, the National Health Service Surveys reported a growth in total health expenditure from 2009.It expanded its three primary social health insurance schemes to cover more than 95% of the population.Such factors promote market growth.However, the high competition and strict approval process hamper the market growth.REGIONAL INSIGHTSThe global peripheral artery disease market growth analysis includes the assessment of North America, Europe, Asia-Pacific, and Rest of World.Asia-Pacific is evaluated to fare the highest in terms of CAGR by 2028.There is a growing demand for advanced peripheral disease devices in the region due to the rising aging population.COMPETITIVE INSIGHTSThere is high competition among well-established players of the market increasing mergers & acquisitions to expand their product portfolio. Some of the key players in the market include Biotronik Inc, Bayer AG, Abbott Laboratories, Angiodynamics Inc, B Braun Melsungen AG, etc.Our report offerings include:• Explore key findings of the overall market• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions• Market Segmentation cater to a thorough assessment of key segments with their market estimations• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developmentsCompanies mentioned1. ABBOTT LABORATORIES2. ANGIODYNAMICS INC3. BAYER AG4. B BRAUN MELSUNGEN AG5. BIOTRONIK INC6. BECTON, DICKINSON AND COMPANY (C R BARD)7. BOSTON SCIENTIFIC CORPORATION8. CARDINAL HEALTH INC9. COOK MEDICAL INC10. KONINKLIJKE PHILIPS NV (PHILIPS)11. MEDTRONIC PLC12. TELEFLEX MEDICAL13. TERUMO CORPORATIONRead the full report: https://www.reportlinker.com/p06064352/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
On 23 November 2020, MT Højgaard Holding A/S announced that a share buy-back programme of an aggregated price of up to DKK 15,000,000 was launched with the purpose to meet obligations arising from the company’s share-based incentive programme. The share buy-back programme is executed pursuant to the so-called ”Safe Harbour” provisions in Regulation (EU) No. 596/2014 of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016. The programme will end no later than on 30 September 2021. The following transactions have been executed from 12 to 16 April 2021: Number ofshares Average purchaseprice (DKK) Transactionvalue (DKK) Accumulated, last announcement 48,420 175.92 8.518.027 12. April 202113. April 2021 14. April 202115. April 2021 16. April 2021 600400600 600 500 196.50 199.93 199.29 200.17 201.39 117,90079,972 119,574 120.102 100,695 Accumulated under the programme 51,120 9,056,270 A detailed overview of transactions executed during the period 12 April to 16 April 2021 is attached to this announcement. Following the above transactions, MT Højgaard Holding A/S owns a total of 51,120 treasury shares, corresponding to 0.656% of the company’s total share capital. Contact: CFO Martin Stig Solberg may be contacted by phone on +45 2270 9365 Attachments MTHH_Company Announcement 26_2021 Appendix - Overview of transactions (12-16 April 2021)
The "Beer Market in India 2021" report has been added to ResearchAndMarkets.com's offering.
The monarch will turn 95 on Wednesday, four days after Philip’s funeral.
Culture secretary to make statement on European Super League planMinisters under pressure to act over proposal for six leading English clubs to join breakaway competitionEuropean Super League – live updates Real Madrid and Liverpool are two of the clubs involved in the proposed league. Photograph: Javier García/BPI/Rex/Shutterstock
The "Plastics Injection Molding Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
Professor Danny Altmann, of Imperial College London, warned variants ‘do pose a threat’ and ‘we still have a very large vulnerable population’.
The Times said the Prime Minister plans to make it a criminal offence not to declare work for a foreign government in the UK.
Dublin, April 19, 2021 (GLOBE NEWSWIRE) -- The "Disease Analysis: Dengue Vaccines" report has been added to ResearchAndMarkets.com's offering. The dengue vaccines market is expected to expand rapidly following the anticipated launch of TAK-003 in 2021/22. The pipeline remains active with two late-phase live-attenuated vaccines (LAVs), Takeda's TAK-003 and Merck & Co's TV003/TV005, in development in dengue-endemic regions. TV003/TV005 was initially developed by the US National Institute of Allergy and Infectious Diseases (NIAID) and has been licensed to the Butantan Institute in Brazil, where it is in Phase III trials; Merck & Co in the US, Canada, China, Europe, and Japan; and various other developers in India, the Middle East, and Asia-Pacific markets, with the goal of ensuring market access by facilitating cheaper domestic production in key dengue-endemic regions.As the first-to-market vaccine with strong efficacy against severe dengue (67-80% reduction in hospitalization rates), Dengvaxia was anticipated to generate blockbuster sales; however, the vaccine has been a commercial failure with sales as low as $4m in 2017. This is primarily due to post-marketing safety issues, with a disproportionate efficacy to DENV-4 hypothesized to be the reason for an increased risk of hospitalization in seronegative individuals (placebo 1.87% vs 3.06% treated). Following revisions to WHO guidelines in 2018, Dengvaxia's use was restricted to seropositive individuals, which substantially reduced its target population. Given that most dengue-endemic regions consist of low-income countries, they are unlikely to implement the necessary serostatus screening programs that would allow identification of individuals eligible to receive Dengvaxia. With two pipeline candidates demonstrating efficacy regardless of serostatus and improved dosing schedules, Dengvaxia is under threat of obsolescence.TAK-003, a second-generation LAV, is the most promising pipeline candidate and is expected to supersede Dengvaxia. Given TAK-003's clean safety profile, better dosing schedule, and strong efficacy in both seronegative and seropositive individuals, the publisher expects that it will rapidly capture market-leader status. Phase III data indicate that TAK-003 has a major competitive advantage of being efficacious regardless of serostatus, which makes it a much more attractive candidate for national immunization programs, since parallel serostatus screening programs are not required. Importantly, this also places TAK-003 in a position to establish a monopoly in the lucrative traveler market, given that Dengvaxia's inconvenient dosing schedule and lack of efficacy in seronegative individuals effectively preclude its use in this setting. Additional advantages include the vaccine's favorable two-dose schedule (0 and 3 months), which will likely have a higher compliance rate than Dengvaxia's three-dose regimen (0, 6, 12 months), and the wider target age range (4-16 years), which will address the unmet need of providing an immunization strategy for younger children.Having reported strong Phase II immunogenicity data with a balanced tetravalent immunogenic response as well as providing protection in a human challenge study, Merck & Co's TV003/TV005 is another threat to Dengvaxia. TV003/TV005 remains behind TAK-003 in development, with a Phase III trial in Brazil assessing the vaccine's safety and efficacy expected to be completed in H2 2021. If the vaccine demonstrates the expected protection against all four serotypes in both seropositive and seronegative individuals, it will be in a strong position to compete with TAK-003. Notably, a strong response against DENV-3 would be highly desirable for TV003, since TAK-003 showed lesser efficacy against this serotype in its pivotal TIDES study. An additional advantage of the vaccine will be its single-dose schedule, which is superior to TAK-003's two-dose (0 and 3 months) and Dengvaxia's three-dose (0, 6, 12 months) schedules. A single-dose vaccine will also be particularly attractive as a travel vaccine, since this is more convenient and can be administered at short notice.GlaxoSmithKline, the Walter Reed Army Institute of Research (WRAIR), and the Oswaldo Cruz Foundation have evaluated a tetravalent purified formalin-inactivated virus vaccine, DPIV, though as GlaxoSmithKline does not list any dengue vaccines in its pipeline, it is unclear whether the company intends to further develop the vaccine. So far, the vaccine has demonstrated promising results in two Phase I trials, with tetravalent neutralizing antibody responses in all vaccinated individuals. An inactivated vaccine has potential advantages over LAVs as it can be administered safely to immunocompromised individuals and is also less likely to run into the issue of serotype interference, whereby one strain replicates more efficiently, leading to an imbalanced immune response to one serotype and lesser responses to remaining serotypes. To date, the publisher has not identified any additional planned or ongoing studies for DPIV.In addition to favorable efficacy and safety profiles, tiered pricing strategies will also play a major role in the success of vaccines. With many dengue-endemic markets being unable to afford expensive public immunization programs at premium prices typically accepted by more developed US/EU markets, lower prices that reflect lesser ability to pay will be needed to improve access in low-income countries. Lower profitability in public sector immunization programs will be offset by higher profitability in private and traveler markets, where premium prices can be achieved. Future competition from cheaper domestically produced versions of TV003/TV005 in Brazil and certain Asia-Pacific countries could also lock out branded vaccines from the public sectors of these markets. Exportation to other dengue-endemic markets could also pose a serious strategic threat to Takeda's TAK-003.The overall likelihood of approval of a Phase I antiviral asset is 12.9%, and the average probability a product advances from Phase III is 68.5%. Antiviral products, on average, take 8.4 years from Phase I to approval, compared to 9.0 years in the overall infectious disease space. Key Topics Covered: OVERVIEWDISEASE BACKGROUND DefinitionTransmissionDiagnosisRisk factorsPatient segmentationSymptoms PREVENTION AND TREATMENT Prevention and controlTreatment guidelines for dengue infection MARKETED VACCINESPIPELINE VACCINESKEY REGULATORY EVENTS EU Fast-Track Review In Store for Takeda's Dengue Vaccine PROBABILITY OF SUCCESSCLINICAL TRIAL LANDSCAPE Sponsors by statusSponsors by phaseRecent events VACCINE ASSESSMENT MODEL DengvaxiaTAK-003TV003/TV005DPIV AGS-v PLUSMARKET DYNAMICSFUTURE TRENDS Dengvaxia's uptake will remain minimal before pipeline rivals launchTAK-003 will become the new market leader, driving considerable market growthApprovals of TV003/TV005 and domestic vaccines will lead to considerable competition CONSENSUS FORECASTSRECENT EVENTS AND ANALYST OPINION TAK-003 for Dengue Fever (March 17, 2020)TAK-003 for Dengue Fever (March 17, 2020) KEY UPCOMING EVENTSUNMET NEEDSBIBLIOGRAPHY Prescription information For more information about this report visit https://www.researchandmarkets.com/r/laxjg9 CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
World shares traded near record highs on Monday, as markets were generally upbeat about the prospects for a global economic recovery from COVID-19, ahead of a busy week for earnings. MSCI world equity index, which tracks shares in 49 countries, was flat on the day, having come close to but not surpassed Friday's record high. MSCI's main European Index was up 0.1%.
A different kind of police failing takes centre stage.
The "Cosmetic & Toiletry Containers Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
Morrison last year said his government would appoint a permanent national commissioner to investigate suicides among current and former military personnel amid rising public anger over the issue.The scheme, however, was marred by delays - prompting a bipartisan support from Australia's Senate for the Royal Commission earlier this year. Tweaking his plans, Morrison said Australia will now hold a Royal Commission to examine any systemic issues among suicides by veterans, while the permanent national commissioner will be tasked with ensuring the recommendations are enforced.Morrison last week said Australia will withdraw its remaining 80 military personnel in Afghanistan after the United States announced it would pull out from the country to end its longest war. The deployment to Afghanistan is part of more than 3,000 Australian troops deployed around the world.
This will be the first crew flight using a recycled Falcon and Dragon as both were designed for reuse.
As Indian women, we need to be aware of our rights and laws to be able to fight any injustice that we may face at our workplaces or in society
National cabinet agrees to fast-track AstraZeneca vaccinations for over-50s. Prime minister says Covid vaccine ‘safe and effective’ for older age group while dismissing prospect of relaxing border restrictions
KEY FINDINGS The global multi-layer ceramic capacitor market is forecasted to progress with a CAGR of 5. 25% over the estimated period. The market growth is primarily accredited to the augmenting consumer electronics industry, the improved frequency characteristics of multi-layer ceramic capacitors, and the increased demand across the automotive sector.New York, April 19, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "GLOBAL MULTI-LAYER CERAMIC CAPACITOR MARKET FORECAST 2021-2028" - https://www.reportlinker.com/p06064353/?utm_source=GNW MARKET INSIGHTSMulti-layer ceramic capacitors are made of alternating layers of metallic electrodes as well as dielectric ceramic.Representing essential building blocks installed in modern electronics, they contribute to nearly 30% of the overall components within a standard hybrid circuit model.Since the potential of multi-layer ceramic capacitors are highly significant, new technologies like 5G, EVs, and IOT, are highly dependent on their availability.Multi-layer ceramic capacitors have low equivalent series resistance (ESR), entailing the resistance component of a capacitor’s internal electrode.High ESR leads to an increased amount of heat generated, owing to the resistance component, in addition to degrading the impedance’s frequency.As a result, low ESRs observe a high demand, particularly when a capacitor is mounted around a semiconductor chip for decoupling to absorb noise. Hence, the impedance is improved on account of multi-layer ceramic capacitors’ frequency characteristics, thereby fueling the market growth.REGIONAL INSIGHTSThe global multi-layer ceramic capacitor market growth is studied through the assessment of the Asia-Pacific, Europe, North America, and Rest of World.The Asia-Pacific is set to be the dominating region over the forecasted period.The region’s automobile market is predominantly dominated by South Asian nations, constituting some of the most significant manufacturers, such as Nissan, Toyota Motor Corporation, and others.The Asia-Pacific also holds a vital position across the global automotive value chain.Hence, these factors essentially supplement the market growth of the region.COMPETITIVE INSIGHTSThere is a significant gap between the supply and demand of multi-layer ceramic capacitors.Moreover, owing to the increasing demand, manufacturers focus on a lesser number of applications and sectors.Some of the leading players operating in the market are Samsung Electro-Mechanics Co Ltd, Kemet Corporation, Murata Manufacturing Co Ltd, etc.Our report offerings include:• Explore key findings of the overall market• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions• Market Segmentation cater to a thorough assessment of key segments with their market estimations• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developmentsCompanies mentioned1. API TECHNOLOGIES CORP 2. DARFON ELECTRONICS CORP3. EYANG TECHNOLOGY DEVELOPMENT CO LTD 4. KEMET CORPORATION 5. KNOWLES ELECTRONICS LLC 6. KYOCERA CORPORATION (AVX CORPORATION) 7. MURATA MANUFACTURING CO LTD8. SAMSUNG ELECTRO-MECHANICS CO LTD 9. TAIYO YUDEN CO LTD10. TDK CORPORATION 11. VISHAY INTERTECHNOLOGY INC 12. WALSIN TECHNOLOGY CORPORATION 13. WÜRTH ELEKTRONIK GROUP 14. YAGEO CORPORATIONRead the full report: https://www.reportlinker.com/p06064353/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001